SRPT - Sarepta Therapeutics, Inc.

QQQ $ 480.15 $ -1.15 (-0.24 %)

DIA $ 408.54 $ -0.35 (-0.09 %)

SPY $ 558.65 $ -0.51 (-0.09 %)

TLT $ 98.68 $ 0.38 (0.39 %)

GLD $ 232.46 $ -1.26 (-0.54 %)

Previous Close

$ 140.49

Open

$ 139.58

Bid

$ 126.57 x 100

Ask

$ 140.71 x 200

Day's Range

$ 138.94 - $ 142.69

52 Week Range

$ 55.25 - $ 173.25

Volume

693,415

Average Volume

Market Cap

13.61B

Beta (5Y Monthly)

$ 0.78

PE Ratio (TTM)

$ 285.97

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-07-2024	06-30-2024	10-Q
2	05-01-2024	03-31-2024	10-Q
3	02-28-2024	12-31-2023	10-K
4	11-01-2023	09-30-2023	10-Q
5	08-02-2023	06-30-2023	10-Q
6	05-02-2023	03-31-2023	10-Q
7	02-28-2023	12-31-2022	10-K
8	11-02-2022	09-30-2022	10-Q
9	08-02-2022	06-30-2022	10-Q
10	05-04-2022	03-31-2022	10-Q
11	03-01-2022	12-31-2021	10-K
12	11-03-2021	09-30-2021	10-Q
13	08-04-2021	06-30-2021	10-Q
14	05-05-2021	03-31-2021	10-Q
15	03-01-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-05-2020	06-30-2020	10-Q
18	05-06-2020	03-31-2020	10-Q
19	02-26-2020	12-31-2019	10-K
20	11-07-2019	09-30-2019	10-Q
21	08-07-2019	06-30-2019	10-Q
22	05-08-2019	03-31-2019	10-Q
23	02-28-2019	12-31-2018	10-K
24	10-31-2018	09-30-2018	10-Q
25	08-08-2018	06-30-2018	10-Q
26	05-03-2018	03-31-2018	10-Q
27	03-01-2018	12-31-2017	10-K
28	11-01-2017	09-30-2017	10-Q
29	08-03-2017	06-30-2017	10-Q
30	05-04-2017	03-31-2017	10-Q
31	02-28-2017	12-31-2016	10-K
32	11-07-2016	09-30-2016	10-Q
33	08-09-2016	06-30-2016	10-Q
34	05-05-2016	03-31-2016	10-Q
35	02-25-2016	12-31-2015	10-K
36	11-05-2015	09-30-2015	10-Q
37	08-06-2015	06-30-2015	10-Q
38	05-07-2015	03-31-2015	10-Q
39	02-26-2015	12-31-2014	10-K
40	11-06-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

how-is-the-market-feeling-about-sarepta-therapeutics

How Is The Market Feeling About Sarepta Th...
08/16/2024 16:15:18

A Closer Look at 28 Analyst Recommendation...
08/15/2024 16:00:36

RBC Capital Reiterates Outperform on Sarep...
08/15/2024 14:35:27

RBC Capital analyst Brian Abrahams reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $181 price ...

100-invested-in-this-stock-10-years-ago-would-be-worth-600-today

$100 Invested In This Stock 10 Years Ago W...
08/12/2024 14:30:21

Warner Bros, Airbnb And Monster Beverage A...
08/11/2024 15:53:29

These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. be...

RBC Capital Maintains Outperform on Sarept...
08/08/2024 20:11:55

RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and lowers the price targe...

Smart Money Is Betting Big In SRPT Options
08/08/2024 19:31:18

Citigroup Maintains Neutral on Sarepta The...
08/08/2024 19:06:45

Citigroup analyst David Hoang maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $...

Cantor Fitzgerald Maintains Neutral on Sar...
08/08/2024 14:50:19

Cantor Fitzgerald analyst Kristen Kluska maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price ta...

Evercore ISI Group Upgrades Sarepta Therap...
08/08/2024 13:22:28

Evercore ISI Group analyst Gavin Clark-Gartner upgrades Sarepta Therapeutics (NASDAQ:SRPT) from In-Line to Outperform and lo...

Barclays Maintains Overweight on Sarepta T...
08/08/2024 12:25:34

Barclays analyst Gena Wang maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and lowers the price target from $...

mckesson-reports-weak-sales-joins-jfrog-fastly-warner-bros-discovery-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session

McKesson Reports Weak Sales, Joins JFrog, ...
08/08/2024 12:20:45

Piper Sandler Maintains Overweight on Sare...
08/08/2024 11:27:39

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and lowers the price target ...

Sarepta Therapeutics Sees FY25 Net Product...
08/07/2024 20:37:42

Sarepta Therapeutics Q2 2024 Adj. EPS $0.4...
08/07/2024 20:09:44

Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of ...

26 Analysts Have This To Say About Sarepta...
07/29/2024 15:00:22

RBC Capital Upgrades Sarepta Therapeutics ...
07/29/2024 10:40:40

RBC Capital analyst Brian Abrahams upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Sector Perform to Outperform and announc...

heres-how-much-1000-invested-in-sarepta-therapeutics-10-years-ago-would-be-worth-today

Here's How Much $1000 Invested In Sarepta ...
07/18/2024 18:30:24

jim-cramer-says-dont-sell-match-group-youve-just-got-a-very-very-smart-investor-in-there

Jim Cramer Says Don't Sell Match Group: 'Y...
07/17/2024 12:55:11

Jim Cramer doesn't favor Fortinet, but owns Palo Alto Networks for charity. Air Products not doing well due to better run c...

heres-how-much-100-invested-in-sarepta-therapeutics-10-years-ago-would-be-worth-today

Here's How Much $100 Invested In Sarepta T...
07/04/2024 14:30:27

6 Gene Therapy M&A Targets On The Radar
03/27/2019 16:45:40